BC Week In Review | Jan 25, 2019
Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Jan. 23 in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia...
BC Extra | Jan 23, 2019
Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Wednesday in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia and...
BC Week In Review | Jun 22, 2018
Company News

BridgeBio launches mitochondrial-focused subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched Fortify Therapeutics Inc. June 18 with $20 million and an exclusive license to compounds from NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NEVPF) to treat Leber’s hereditary optic neuropathy. Fortify will...
BC Extra | Jun 18, 2018
Company News

BridgeBio launches mitochondrial-focused subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched Fortify Therapeutics Inc. on Monday with $20 million and an exclusive license to compounds from NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NEVPF) to treat Leber’s hereditary optic neuropathy. Fortify will...
BC Week In Review | Jun 15, 2018
Company News

BridgeBio launches rare genetic disorder subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched another subsidiary, forming CoA Therapeutics Inc. to develop small molecules which increase coenzyme A levels to treat rare genetic disorders. CoA CEO Shafique Virani told BioCentury that the...
BC Week In Review | Jun 15, 2018
Company News

Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on June 11, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also...
BC Extra | Jun 13, 2018
Company News

BridgeBio launches rare genetic disorder subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched another subsidiary this week, forming CoA Therapeutics Inc. to develop small molecules which increase coenzyme A levels to treat rare genetic disorders. CoA CEO Shafique Virani told BioCentury...
BC Extra | Jun 11, 2018
Company News

Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on Monday, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also divested...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BC Week In Review | Jul 28, 2017
Company News

Alexion announces pipeline restructuring

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc. (Cambridge, Mass.), Blueprint Medicines...
Items per page:
1 - 10 of 19